Pfizer (PFE) EPS (Basic) (2009 - 2026)

Pfizer (PFE) posted quarterly EPS (Basic) of -$0.0 for Q1 2026, down 151.95% quarter-over-quarter from $0.0 in Q2 2025.

Pfizer (PFE) EPS (Basic) (2009 - 2026) Analysis & Trends

Pfizer (PFE) has reported EPS (Basic) for 18 consecutive years, with -$0.0 the latest figure, recorded in Q1 2026.

In Q1 2026, EPS (Basic) changed N/A year-over-year to -$0.0; the TTM figure through Mar 2026 stood at $0.0 (up 32.96% YoY), while the FY2025 annual figure was $0.0, up 126.51% from the prior year.
EPS (Basic) eased to -$0.0 in Q1 2026 per PFE's latest filing, from $0.0 in the prior quarter.
Across five years, EPS (Basic) topped out at $0.01 in Q3 2022 and bottomed at -$0.0 in Q4 2023.
Historically, EPS (Basic) has averaged $0.0 across 5 years, with a median of -$0.0 in 2024.
Annual changes were most pronounced in 2022 — EPS (Basic) plunged 994.71% — and 2024, when it jumped 947.0%.
Pfizer's EPS (Basic) stood at $0.01 in 2022, then sank by 175.79% to -$0.0 in 2023, then jumped by 69.36% to -$0.0 in 2024, then surged by 411.51% to $0.0 in 2025, then plunged by 151.95% to -$0.0 in 2026.
Business Quant data shows PFE's EPS (Basic) at -$0.0 in Q1 2026, $0.0 in Q2 2025, and -$0.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Johnson & Johnson	645.88 Bn	625.12 Bn	17.26 Bn	2.30
2	AbbVie	463.46 Bn	456.89 Bn	12.70 Bn	2.04
3	Merck	367.92 Bn	360.78 Bn	12.21 Bn	-0.54
4	Novartis Ag	297.71 Bn	290.02 Bn	11.24 Bn	1.71
5	Astrazeneca	255.55 Bn	250.65 Bn	12.86 Bn	1.62
6	Amgen	234.52 Bn	220.53 Bn	7.24 Bn	4.40
7	Gilead Sciences	178.22 Bn	175.04 Bn	6.22 Bn	-8.44
8	Pfizer	158.57 Bn	146.88 Bn	10.94 Bn	-0.04
9	Gsk	105.32 Bn	101.15 Bn	8.24 Bn	0.29
10	Sanofi	54.20 Bn	46.82 Bn	10.79 Bn	0.33

Download Data